International Recognition for JFMED CU
At the prestigious 5th International Prostate Cancer Symposium and World Urologic Oncology Symposium, doctors and scientists from the Jessenius Faculty of Medicine, Comenius University (JFMED CU) in Martin received a significant international award.
This event has long focused on presenting multidisciplinary approaches to innovative diagnostics and treatments for prostate cancer, covering a wide range of topics, from molecular testing and screening to patient education and comprehensive treatment, with a strong emphasis on new therapeutic approaches.
"Our team from the Urology Clinic at JFMED CU and University Hospital Martin, the Institute of Medical Biochemistry, the Institute of Clinical Biochemistry, and the Biomedical Centre Martin (BioMed) has been intensively working for years on the research and development of new diagnostic and screening oncomarkers for malignant prostate diseases," stated Róbert Dušenka, MD, PhD, MBA, assistant professor at the Urology Clinic of JFMED CU and University Hospital Martin, who attended the symposium in New York. He added that the JFMED CU experts presented a study focusing on the development of new genetic and molecular oncomarkers.
"Specifically, our team’s work explores the influence of genetic variations in selected genes on the risk of prostate cancer. This contribution earned us international recognition and an award for 2nd place. This award is a significant acknowledgment of our scientific research activities at our alma mater, which have reached a world-class level. We are all rightfully proud of this success. I am convinced that continued support for scientific research activities will remain a top priority, bringing further international achievements not only for our team but also for other colleagues at JFMED CU, of whom our alma mater can be justly proud," Dr. Dušenka shared.
The International Prostate Cancer Symposium and World Urologic Oncology Symposium was organized by the world-renowned Mount Sinai University in New York, under the patronage of Professor Ashutosh Tewari, MBBS, MCh, FRCS (Hon), head of the urology department and president of the event from the Icahn School of Medicine at Mount Sinai, New York, USA.
"Special attention was given to genetic and molecular techniques that enable the identification of new prognostic-diagnostic markers, as well as to surgical procedures utilizing robotic surgery and 3D online operations. The event featured over 80 renowned experts from around the world, including Prof. Tewari, Prof. Badani, Prof. Wiklund, and other internationally recognized specialists in urologic oncology," added Dr. Róbert Dušenka.
